Skip to main content
Scroll Top
Menu
WHO WE ARE
ABOUT US
TEAM
MANAGEMENT TEAM
INDUSTRIAL ADVISORS
SCIENTIFIC COUNCIL
PARTNERS
R&D
INTRODUCTION
TECH
NEUROSTIMULATION
PHOTOBIOMODULATION
ALZHEIMER
CLINICAL TRIAL
PATHOPHYSIOLOGY
TECHNOLOGY
CONCUSSION
CLINICAL TRIAL
PATHOPHYSIOLOGY
TECHNOLOGY
SOLUTIONS
CLINICAL RESEARCH
PRECLINICAL RESEARCH
CONCUSSION
NEWS
ALL
PRESS ARTICLES
VIDEOS
EVENTS
SCIENTIFIC PUBLICATIONS
ALL
SCIENTIFIC ARTICLES
ORAL COMMUNICATIONS
POSTED COMMUNICATIONS
CONTACT
FAQ
Executive summary
Français
Menu
WHO WE ARE
ABOUT US
TEAM
MANAGEMENT TEAM
INDUSTRIAL ADVISORS
SCIENTIFIC COUNCIL
PARTNERS
R&D
INTRODUCTION
TECH
NEUROSTIMULATION
PHOTOBIOMODULATION
ALZHEIMER
CLINICAL TRIAL
PATHOPHYSIOLOGY
TECHNOLOGY
CONCUSSION
CLINICAL TRIAL
PATHOPHYSIOLOGY
TECHNOLOGY
SOLUTIONS
CLINICAL RESEARCH
PRECLINICAL RESEARCH
CONCUSSION
NEWS
ALL
PRESS ARTICLES
VIDEOS
EVENTS
SCIENTIFIC PUBLICATIONS
ALL
SCIENTIFIC ARTICLES
ORAL COMMUNICATIONS
POSTED COMMUNICATIONS
CONTACT
FAQ
Executive summary
Français
Home
Tag
REGEnLIFE: a new step towards a practical and accessible treatment to address the public health challenges posed by Alzheimer’s disease.
Alzheimer
22 August 2026
REGEnLIFE: a new step towards a practical and accessible treatment to address the public health challenges posed by Alzheimer’s disease.
Research. Regenlife is testing its technologies for Alzheimer’s disease at Biofortis in Nantes
Alzheimer
22 August 2026
Research. Regenlife is testing its technologies for Alzheimer’s disease at Biofortis in Nantes
Regenlife opens a clinical research centre at Biofortis in Nantes to study Alzheimer’s disease
Alzheimer
22 August 2026
Regenlife opens a clinical research centre at Biofortis in Nantes to study Alzheimer’s disease
REGEnLIFE Appoints Dr. Volker Herrmann as CEO to accelerate corporate growth and global expansion
Past Events
22 August 2026
REGEnLIFE Appoints Dr. Volker Herrmann as CEO to accelerate corporate growth and global expansion
Montpellier: Regenlife sheds light on the fight against Alzheimer’s disease
Alzheimer
28 May 2026
Montpellier: Regenlife sheds light on the fight against Alzheimer’s disease
A helmet and a belt to slow the progression of Alzheimer’s disease: an ingenious idea being tested at the Hospices Civils de Lyon
Alzheimer
28 May 2026
A helmet and a belt to slow the progression of Alzheimer’s disease: an ingenious idea being tested at the Hospices Civils de Lyon
Alzheimer’s disease: REGEnLIFE accelerates its Light4Life clinical trial with the opening of a new trial site at Lyon University Hospital, Hôpital des Charpennes
Alzheimer
1 April 2026
Alzheimer’s disease: REGEnLIFE accelerates its Light4Life clinical trial with the opening of a new trial site at Lyon University Hospital, Hôpital des Charpennes
IN THE SPOTLIGHT – REGEnLIFE: At the crossroads of medicine and physics – Pharmaceutiques Magazine No. 335 / March 2026
Alzheimer
Concussions
16 March 2026
IN THE SPOTLIGHT – REGEnLIFE: At the crossroads of medicine and physics – Pharmaceutiques Magazine No. 335 / March 2026
Slowing down neurodegeneration with light
Alzheimer
16 March 2026
Slowing down neurodegeneration with light
REGEnLIFE, the French NeuroTech DeepTech company shortlisted for the 2025 Prix Galien USA
Alzheimer
16 March 2026
REGEnLIFE, the French NeuroTech DeepTech company shortlisted for the 2025 Prix Galien USA
“Conceiving an innovation is one thing; bringing it to fruition is quite another.” Guillaume Blivet wants to transform the lives of patients with neurological disorders
Alzheimer
Depression
Multiple sclerosis
16 March 2026
“Conceiving an innovation is one thing; bringing it to fruition is quite another.” Guillaume Blivet wants to transform the lives of patients with neurological disorders
Can Light Heal the Brain? REGEnLIFE Explores Photobiomodulation for Alzheimer’s
Alzheimer
Depression
Multiple sclerosis
15 March 2026
Can Light Heal the Brain? REGEnLIFE Explores Photobiomodulation for Alzheimer’s
1
2
…
4
Next
Get a Quote
Hidden fields